Trexquant Investment LP Has $524,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Trexquant Investment LP lessened its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNFree Report) by 39.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,122 shares of the specialty pharmaceutical company’s stock after selling 11,887 shares during the period. Trexquant Investment LP’s holdings in Supernus Pharmaceuticals were worth $524,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of SUPN. Vanguard Group Inc. grew its position in shares of Supernus Pharmaceuticals by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,072,180 shares of the specialty pharmaceutical company’s stock valued at $167,410,000 after buying an additional 28,711 shares during the last quarter. Armistice Capital LLC grew its position in shares of Supernus Pharmaceuticals by 1.1% in the 3rd quarter. Armistice Capital LLC now owns 5,092,000 shares of the specialty pharmaceutical company’s stock valued at $140,386,000 after buying an additional 56,000 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Supernus Pharmaceuticals by 6.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,456,369 shares of the specialty pharmaceutical company’s stock valued at $71,089,000 after buying an additional 141,586 shares during the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Supernus Pharmaceuticals by 8.6% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,730,269 shares of the specialty pharmaceutical company’s stock valued at $47,703,000 after purchasing an additional 136,964 shares in the last quarter. Finally, Polar Capital Holdings Plc boosted its position in shares of Supernus Pharmaceuticals by 10.0% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,654,470 shares of the specialty pharmaceutical company’s stock valued at $45,614,000 after purchasing an additional 150,000 shares in the last quarter.

Wall Street Analyst Weigh In

Separately, Piper Sandler cut their target price on Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 28th.

View Our Latest Report on SUPN

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $27.12 on Friday. Supernus Pharmaceuticals, Inc. has a one year low of $21.99 and a one year high of $35.96. The stock’s 50-day moving average is $30.24 and its 200 day moving average is $29.35.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total value of $128,133.16. Following the transaction, the vice president now owns 8,570 shares in the company, valued at $282,724.30. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total value of $128,133.16. Following the transaction, the vice president now owns 8,570 shares in the company, valued at $282,724.30. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 12,364 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total value of $436,572.84. Following the completion of the transaction, the vice president now owns 8,570 shares in the company, valued at approximately $302,606.70. The disclosure for this sale can be found here. Insiders have sold a total of 30,739 shares of company stock worth $1,076,383 in the last 90 days. Corporate insiders own 8.76% of the company’s stock.

About Supernus Pharmaceuticals

(Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Further Reading

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.